ARMP · Insider Trading
Armata Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by ARMP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-14 | Deborah Birx | Chief Executive Officer | F | −14,041 | −$59.81K |
| 2026-04-28 | Daniel B. Gilmer | Director | A | +51,280 deriv. | — |
| 2026-03-17 | Pierre Kyme | Chief Business Officer | F | −1,030 | −$10.86K |
| 2026-03-17 | Deborah Birx | Chief Executive Officer | F | −4,919 | −$51.85K |
| 2026-03-11 | Todd C. Peterson | Director | A | +25,640 deriv. | — |
| 2026-03-11 | Sarah J. Schlesinger | Director | A | +25,640 deriv. | — |
| 2026-03-11 | Pierre Kyme | Chief Business Officer | A | +183,142 deriv. | — |
| 2026-03-11 | Deborah Birx | Chief Executive Officer | A | +421,226 deriv. | — |
| 2026-03-11 | Kostas D Odysseas | Director | A | +25,640 deriv. | — |
| 2026-03-11 | Robin Kramer | Director | A | +25,640 deriv. | — |
| 2026-03-11 | Joseph M Patti | Director | A | +25,640 deriv. | — |
| 2026-03-11 | Jules Haimovitz | Director | A | +25,640 deriv. | — |
| 2026-03-11 | David Duane House | SVP, Finance, and PFO | A | +109,885 deriv. | — |
| 2025-07-14 | Deborah Birx | Chief Executive Officer | F | −13,637 | −$30.96K |
| 2025-04-25 | Pierre Kyme | Chief Business Officer | F | −1,027 | −$2.00K |
| 2025-04-25 | Deborah Birx | Chief Executive Officer | F | −28,986 | −$73.26K |
| 2025-02-07 | Jules Haimovitz | Director | A | +54,343 deriv. | — |
| 2025-02-07 | David Duane House | SVP, Finance, and PFO | A | +25,000 deriv. | — |
| 2025-02-07 | Kostas D Odysseas | Director | A | +54,343 deriv. | — |
| 2025-02-07 | Deborah Birx | Chief Executive Officer | A | +240,000 deriv. | — |
| 2025-02-07 | Todd C. Peterson | Director | A | +54,343 deriv. | — |
| 2025-02-07 | Joseph M Patti | Director | A | +54,343 deriv. | — |
| 2025-02-07 | Robin Kramer | Director | A | +54,343 deriv. | — |
| 2025-02-07 | Sarah J. Schlesinger | Director | A | +54,343 deriv. | — |
| 2025-02-07 | Pierre Kyme | Chief Business Officer | A | +100,000 deriv. | — |
| 2024-10-03 | David Duane House | SVP, Finance, and PFO | A | +75,000 deriv. | — |
| 2024-03-18 | Kostas D Odysseas | Director | A | +94,009 deriv. | — |
| 2024-03-18 | Joseph M Patti | Director | A | +94,009 deriv. | — |
| 2024-03-18 | Todd C. Peterson | Director | A | +94,009 deriv. | — |
| 2024-03-18 | Sarah J. Schlesinger | Director | A | +94,009 deriv. | — |
| 2024-03-18 | Richard Rychlik | Corporate Controller and PFO | A | +10,000 | — |
| 2024-03-18 | Robin Kramer | Director | A | +94,009 deriv. | — |
| 2024-03-18 | Jules Haimovitz | Director | A | +94,009 deriv. | — |
| 2024-03-18 | Deborah Birx | Chief Executive Officer | A | +60,000 | — |
| 2023-12-26 | Richard Rychlik | Corporate Controller and PFO | A | +50,000 deriv. | — |
| 2023-12-26 | Todd C. Peterson | Director | A | +10,461 deriv. | — |
| 2023-12-26 | Kostas D Odysseas | Director | A | +10,461 deriv. | — |
| 2023-12-26 | Robin Kramer | Director | A | +10,461 deriv. | — |
| 2023-12-26 | Jules Haimovitz | Director | A | +10,461 deriv. | — |
| 2023-12-26 | Deborah Birx | Chief Executive Officer | A | +200,000 | — |
| 2023-12-26 | Joseph M Patti | Director | A | +10,461 deriv. | — |
| 2023-12-26 | Sarah J. Schlesinger | Director | A | +10,461 deriv. | — |
| 2023-01-12 | Innoviva, Inc. | Director | Buy | — | — |
| 2022-04-15 | Robin Kramer | Director | A | +33,000 deriv. | — |
| 2022-04-15 | Todd Patrick | Director | A | +33,000 deriv. | — |
| 2022-04-15 | Duane Alfred Morris | VP of Operations | A | +41,000 deriv. | — |
| 2022-04-15 | Joseph M Patti | Director | A | +33,000 deriv. | — |
| 2022-04-15 | Brian Varnum | President and CEO | A | +240,000 deriv. | — |
| 2022-04-15 | Kostas D Odysseas | Director | A | +33,000 deriv. | — |
| 2022-04-15 | Jules Haimovitz | Director | A | +33,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Deborah Birx | Chief Executive Officer | 198,417 | $722.24K |
| Pierre Kyme | Chief Business Officer | 9,461 | $34.44K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARMP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.